Somatic mutations activating STAT3 in human inflammatory hepatocellular adenomas

Journal of Experimental Medicine

Volumn 208, Issue 7, 2011, Pages 1359-1366

  Pilati, Camilla ^a,b   Amessou, Mohamed ^a,b   Bihl, Michel P ^a,b   Balabaud, Charles ^a   Van Nhieu, Jeanne Tran ^c   Paradis, Valérie ^d   Nault, Jean Charles ^a,b   Izard, Tina ^e   Bioulac Sage, Paulette ^a,f   Couchy, Gabrielle ^a,b   Poussin, Karine ^a,b   Zucman Rossi, Jessica ^a,b,g  

^a INSERM   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^d BEAUJON HOSPITAL   (France)

^e SCRIPPS RESEARCH INSTITUTE   (United States)

^f HÔPITAL PELLEGRIN   (France)

^g HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 6; JANUS KINASE 1; MUTANT PROTEIN; PROTEIN TYROSINE KINASE; STAT3 PROTEIN; TYROSINE;

ADULT; AMINO ACID SUBSTITUTION; ARTICLE; CARCINOGENESIS; FEMALE; GENE SILENCING; HUMAN; HUMAN TISSUE; HYPERSENSITIVITY; INFLAMMATION; INFLAMMATORY HEPATOCELLULAR ADENOMA; LIVER ADENOMA; LIVER CELL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; SOMATIC MUTATION; WILD TYPE;

ACTIVE TRANSPORT, CELL NUCLEUS; ADENOMA, LIVER CELL; ADULT; AGED; BASE SEQUENCE; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CYTOKINE RECEPTOR GP130; DIMERIZATION; DNA, NEOPLASM; FEMALE; HUMANS; INTERLEUKIN-6; LIVER NEOPLASMS; MALE; MIDDLE AGED; MODELS, MOLECULAR; MUTANT PROTEINS; MUTATION; PHOSPHORYLATION; PROTEIN STRUCTURE, QUATERNARY; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; SRC-FAMILY KINASES; STAT3 TRANSCRIPTION FACTOR; TYROSINE;

EID: 79960346759     PISSN: 00221007     EISSN: 15409538     Source Type: Journal    
DOI: 10.1084/jem.20110283     Document Type: Article

References (30)

1. Becker, S., B. Groner, and C.W. Müller. 1998. Three-dimensional structure of the Stat3beta homodimer bound to DNA. Nature. 394:145-151.
2. Bioulac-Sage, P., S. Rebouissou, C. Thomas, J.F. Blanc, J. Saric, A. Sa Cunha, A. Rullier, G. Cubel, G. Couchy, S. Imbeaud, et al. 2007. Hepatocellular adenoma subtype classification using molecular markers and immunohistochemistry. Hepatology. 46:740-748.
3. Bluteau, O., E. Jeannot, P. Bioulac-Sage, J.M. Marqués, J.F. Blanc, H. Bui, J.C. Beaudoin, D. Franco, C. Balabaud, P. Laurent-Puig, and J. Zucman-Rossi. 2002. Bi-allelic inactivation of TCF1 in hepatic adenomas. Nat. Genet. 32:312-315.
4. Bromberg, J.F., M.H. Wrzeszczynska, G. Devgan, Y. Zhao, R.G. Pestell, C. Albanese, and J.E. Darnell Jr. 1999. Stat3 as an oncogene. Cell. 98:295-303.
5. Chen, X., R. Bhandari, U. Vinkemeier, F. Van Den Akker, J.E. Darnell Jr., and J. Kuriyan. 2003. A reinterpretation of the dimerization interface of the N-terminal domains of STATs. Protein Sci. 12:361-365.
6. Constantinescu, S.N., M. Girardot, and C. Pecquet. 2008. Mining for JAKSTAT mutations in cancer. Trends Biochem. Sci. 33:122-131.
7. Coqueret, O., and H. Gascan. 2000. Functional interaction of STAT3 transcription factor with the cell cycle inhibitor p21WAF1/CIP1/SDI1. J. Biol. Chem. 275:18794-18800.
8. Coulouarn, C., G. Lefebvre, R. Daveau, F. Letellier, M. Hiron, L. Drouot, M. Daveau, and J.P. Salier. 2005. Genome-wide response of the human Hep3B hepatoma cell to proinflammatory cytokines, from transcription to translation. Hepatology. 42:946-955.
9. Cressman, D.E., L.E. Greenbaum, R.A. DeAngelis, G. Ciliberto, E.E. Furth, V. Poli, and R. Taub. 1996. Liver failure and defective hepatocyte regeneration in interleukin-6-deficient mice. Science. 274:1379-1383.
10. Grivennikov, S.I., and M. Karin. 2010. Inflammation and oncogenesis: a vicious connection. Curr. Opin. Genet. Dev. 20:65-71.
11. Grivennikov, S., E. Karin, J. Terzic, D. Mucida, G.Y. Yu, S. Vallabhapurapu, J. Scheller, S. Rose-John, H. Cheroutre, L. Eckmann, and M. Karin. 2009. IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell. 15:103-113.
12. Grivennikov, S.I., F.R. Greten, and M. Karin. 2010. Immunity, inflammation, and cancer. Cell. 140:883-899.
13. Haan, S., M. Kortylewski, I. Behrmann, W. Müller-Esterl, P.C. Heinrich, and F. Schaper. 2000. Cytoplasmic STAT proteins associate prior to activation. Biochem. J. 345:417-421.
14. Hattori, M., L.J. Abraham, W. Northemann, and G.H. Fey. 1990. Acute-phase reaction induces a specific complex between hepatic nuclear proteins and the interleukin 6 response element of the rat alpha 2-macroglobulin gene. Proc. Natl. Acad. Sci. USA. 87:2364-2368.
15. Holland, S.M., F.R. DeLeo, H.Z. Elloumi, A.P. Hsu, G. Uzel, N. Brodsky, A.F. Freeman, A. Demidowich, J. Davis, M.L. Turner, et al. 2007. STAT3 mutations in the hyper-IgE syndrome. N. Engl. J. Med. 357:1608-1619.
16. Inoue, M., M. Minami, M. Matsumoto, T. Kishimoto, and S. Akira. 1997. The amino acid residues immediately carboxyl-terminal to the tyrosine phosphorylation site contribute to interleukin 6-specific activation of signal transducer and activator of transcription 3. J. Biol. Chem. 272:9550-9555.
17. International Working Party. 1995. Terminology of nodular hepatocellular lesions. Hepatology. 22:983-993.
18. Levy, D.E., and J.E. Darnell Jr. 2002. Stats: transcriptional control and biological impact. Nat. Rev. Mol. Cell Biol. 3:651-662.
19. Lütticken, C., U.M. Wegenka, J. Yuan, J. Buschmann, C. Schindler, A. Ziemiecki, A.G. Harpur, A.F. Wilks, K. Yasukawa, T. Taga, et al. 1994. Association of transcription factor APRF and protein kinase Jak1 with the interleukin-6 signal transducer gp130. Science. 263:89-92.
20. Minegishi, Y., M. Saito, S. Tsuchiya, I. Tsuge, H. Takada, T. Hara, N. Kawamura, T. Ariga, S. Pasic, O. Stojkovic, et al. 2007. Dominant-negative mutations in the DNA-binding domain of STAT3 cause hyper-IgE syndrome. Nature. 448:1058-1062.
21. Rebouissou, S., M. Amessou, G. Couchy, K. Poussin, S. Imbeaud, C. Pilati, T. Izard, C. Balabaud, P. Bioulac-Sage, and J. Zucman-Rossi. 2009. Frequent in-frame somatic deletions activate gp130 in inflammatory hepatocellular tumours. Nature. 457:200-204.
22. Scarzello, A.J., A.L. Romero-Weaver, S.G. Maher, T.D. Veenstra, M. Zhou, A. Qin, R.P. Donnelly, F. Sheikh, and A.M. Gamero. 2007. A Mutation in the SH2 domain of STAT2 prolongs tyrosine phosphorylation of STAT1 and promotes type I IFN-induced apoptosis. Mol. Biol. Cell. 18:2455-2462.
23. Schaefer, T.S., L.K. Sanders, and D. Nathans. 1995. Cooperative transcriptional activity of Jun and Stat3 beta, a short form of Stat3. Proc. Natl. Acad. Sci. USA. 92:9097-9101.
24. Shuai, K., C.M. Horvath, L.H. Huang, S.A. Qureshi, D. Cowburn, and J.E. Darnell Jr. 1994. Interferon activation of the transcription factor Stat91 involves dimerization through SH2-phosphotyrosyl peptide interactions. Cell. 76:821-828.
25. Wen, Z., Z. Zhong, and J.E. Darnell Jr. 1995. Maximal activation of transcription by Stat1 and Stat3 requires both tyrosine and serine phosphorylation. Cell. 82:241-250.
26. Yu, H., D. Pardoll, and R. Jove. 2009. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat. Rev. Cancer. 9:798-809.
27. Zhang, T., W.H. Kee, K.T. Seow, W. Fung, and X. Cao. 2000. The coiledcoil domain of Stat3 is essential for its SH2 domain-mediated receptor binding and subsequent activation induced by epidermal growth factor and interleukin-6. Mol. Cell. Biol. 20:7132-7139.
28. Zhang, Y., J. Turkson, C. Carter-Su, T. Smithgall, A. Levitzki, A. Kraker, J.J. Krolewski, P. Medveczky, and R. Jove. 2000. Activation of Stat3 in v-Src-transformed fibroblasts requires cooperation of Jak1 kinase activity. J. Biol. Chem. 275:24935-24944.
29. Zhong, Z., Z. Wen, and J.E. Darnell Jr. 1994. Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. Science. 264:95-98.
30. Zucman-Rossi, J., E. Jeannot, J.T. Nhieu, J.Y. Scoazec, C. Guettier, S. Rebouissou, Y. Bacq, E. Leteurtre, V. Paradis, S. Michalak, et al. 2006. Genotype-phenotype correlation in hepatocellular adenoma: new classification and relationship with HCC. Hepatology. 43:515-524.